Eastern Bank boosted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 34.6% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 263,482 shares of the medical equipment provider’s stock after buying an additional 67,787 shares during the period. Eastern Bank owned approximately 0.09% of Hologic worth $9,667,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of the stock. Davis R M Inc. boosted its stake in Hologic by 2.8% during the third quarter. Davis R M Inc. now owns 823,584 shares of the medical equipment provider’s stock valued at $30,217,000 after buying an additional 22,130 shares during the period. First Trust Advisors LP boosted its stake in Hologic by 161.9% during the third quarter. First Trust Advisors LP now owns 924,576 shares of the medical equipment provider’s stock valued at $33,923,000 after buying an additional 571,512 shares during the period. Northpointe Capital LLC bought a new stake in Hologic during the third quarter valued at $2,831,000. Altfest L J & Co. Inc. bought a new stake in Hologic during the third quarter valued at $507,000. Finally, APG Asset Management N.V. boosted its stake in Hologic by 31.7% during the third quarter. APG Asset Management N.V. now owns 136,751 shares of the medical equipment provider’s stock valued at $5,017,000 after buying an additional 32,923 shares during the period. 96.04% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This article was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2017/11/12/hologic-inc-holx-shares-bought-by-eastern-bank.html.
Several equities research analysts recently issued reports on the company. Piper Jaffray Companies reissued a “buy” rating and set a $48.00 price objective on shares of Hologic in a research note on Thursday. Needham & Company LLC reaffirmed a “buy” rating and set a $50.00 price target on shares of Hologic in a research note on Friday, November 3rd. Zacks Investment Research raised Hologic from a “sell” rating to a “hold” rating in a research note on Tuesday, October 31st. Jefferies Group LLC reaffirmed a “buy” rating and set a $44.00 price target (down previously from $49.00) on shares of Hologic in a research note on Tuesday, October 10th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $45.00 price target (down previously from $48.00) on shares of Hologic in a research note on Monday, October 9th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and nine have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $47.54.
In related news, VP Karleen Marie Oberton sold 1,256 shares of the company’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $39.29, for a total value of $49,348.24. Following the transaction, the vice president now directly owns 9,406 shares of the company’s stock, valued at approximately $369,561.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Lawrence M. Levy sold 9,596 shares of the company’s stock in a transaction that occurred on Tuesday, October 10th. The shares were sold at an average price of $36.81, for a total value of $353,228.76. The disclosure for this sale can be found here. Over the last three months, insiders sold 25,667 shares of company stock worth $969,299. Insiders own 0.79% of the company’s stock.
Hologic, Inc. (HOLX) traded down $0.68 during trading on Friday, reaching $38.97. The company’s stock had a trading volume of 4,908,600 shares, compared to its average volume of 2,736,277. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.65 and a current ratio of 0.79. The company has a market cap of $10,910.63, a PE ratio of 19.63, a price-to-earnings-growth ratio of 1.76 and a beta of 0.93. Hologic, Inc. has a fifty-two week low of $35.76 and a fifty-two week high of $46.80.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The business had revenue of $802.90 million for the quarter, compared to analysts’ expectations of $792.54 million. During the same period in the previous year, the firm posted $0.52 EPS. The business’s revenue was up 10.5% on a year-over-year basis. equities analysts forecast that Hologic, Inc. will post 2.12 EPS for the current year.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.